Merck said a study of its once-daily formulation of ISENTRESS (raltegravir) for the treatment of adults with HIV-1 infection found that after 48 weeks of treatment, 1200 mg raltegravir was statistically non-inferior to the marketed formulation approved dose of ISENTRESS 400 mg twice-daily.

Furthermore, the study showed comparable rates of reported drug-related clinical adverse events and rates of discontinuation between the two treatment groups.

Therefore, this once-daily investigational formulation of raltegravir “has the potential to simplify some HIV-1 infected patients’ regimens, which may be beneficial to those patients as they continue to manage their disease.” said Dr. Pedro Cahn, lead study author and chief of the infectious disease unit at Juan A. Fernandez Hospital in Buenos Aires.